Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells

키워드

참고문헌 (44)

1. Tenter AM, "Toxoplasma gondii : from animals to humans", Int J Parasitol, 30, pp.1217~1258 (2000)
2. McCannel CA, "Causes of uveitis in the general practice of ophthalmology. UCLA community-based Uveitis study group", Am J Ophthalmol, 121, pp.35~46 (1996)
3. Pradhan E, "Antibiotics versus no treatment for toxoplasma retinochoroiditis", Cochrane Database Syst Rev, 20, pp.CD002218~ (2016)
4. Zhaoshou Yang, "Afatinib Reduces STAT6 Signaling of Host ARPE-19 Cells Infected with Toxoplasma gondii", The Korean Journal of Parasitology, 54(1), pp.31~38 (2016), 대한기생충학ㆍ열대의학회
5. Manning G, "The protein kinase complement of the human genome", Science, 298, pp.1912~1934 (2002)
6. Hubbard SR, "Protein tyrosine kinase structure and function", Annu Rev Biochem, 69, pp.373~398 (2000)
7. Levitzki A, "Tyrosine kinase inhibition : an approach to drug development", Science, 267, pp.1782~1788 (1995)
8. Muniz-Feliciano L, "Toxoplasma gondiiinduced activation of EGFR prevents autophagy protein-mediated killing of the parasite", PLoS Pathog, 9, pp.e1003809~ (2013)
9. Peixoto L, "Integrative genomic approaches highlight a family of parasite-specific kinases that regulate host responses", Cell Host Microbe, 8, pp.208~218 (2010)
10. Wei S, "Pyridinylimidazole p38 mitogen-activated protein kinase inhibitors block intracellular Toxoplasma gondii replication", Int J Parasitol, 32, pp.969~977 (2002)
11. Brumlik MJ, "Identification of a novel mitogen-activated protein kinase in Toxoplasma gondii", Int J Parasitol, 34, pp.1245~1254 (2004)
12. Huang H, "Molecular cloning and characterization of mitogen-activated protein kinase 2 in Toxoplasma gondii", Cell Cycle, 10, pp.3519~3526 (2011)
13. Donald RG, "Toxoplasma gondii cyclic GMP-dependent kinase:chemotherapeutic targeting of an essential parasite protein kinase", Eukaryot Cell, 1, pp.317~328 (2002)
14. Kurokawa H, "Identification of Toxoplasma gondii cAMP dependent protein kinase and its role in the tachyzoite growth", PLoS One, 6, pp.e22492~ (2011)
15. Zhaoshou Yang, "Gefitinib inhibits the growth of Toxoplasma gondii in HeLa cells", The Korean Journal of Parasitology, 52(4), pp.439~441 (2014), 대한기생충학ㆍ열대의학회[DOI]
16. Zhang J, "Targeting cancer with small molecule kinase inhibitors", Nat Rev Cancer, 9, pp.28~39 (2009)
17. Sun K, "Screening for inhibition of Vibrio cholerae VipA-VipB interaction identifies small-molecule compounds active against type VI secretion", Antimicrob Agents Chemother, 58, pp.4123~4130 (2014)
18. Lepri S, "Optimization of smallmolecule inhibitors of influenza virus polymerase : from thiophene-3-carboxamide to polyamido scaffolds", J Med Chem, 57, pp.4337~4350 (2014)
19. Belfort Jr R, "Retina", pp.1494~1499 (2013), WB Saunders
20. Carrión-Carrión C, "Fatal Stevens-Johnson syndrome in an AIDS patient treated with sulfadiazine", Ann Pharmacother, 33, pp.379~380 (1999)
21. Wei F, "Protein kinases of Toxoplasma gondii : functions and drug targets", Parasitol Res, 112, pp.2121~2129 (2013)
22. Majem M, "An update on molecularly targeted therapies in second-and third-line treatment in non-small cell lung cancer : focus on EGFR inhibitors and anti-angiogenic agents", Clin Transl Oncol, 15, pp.343~357 (2013)
23. Wang X, "The Potential of panHER Inhibition in Cancer", Front Oncol, 5, pp.2~ (2015)
24. Traxler P, "Tyrosine kinases as targets in cancer therapy-successes and failures", Expert Opinion on Therapeutic Targets, 7, pp.215~234 (2003)
25. Abrams TJ, "SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer", Mol Cancer Ther, 2, pp.471~478 (2003)
26. Hilberg F, "BIBF 1120 : triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy", Cancer Res, 68, pp.4774~4782 (2008)
27. Cross DA, "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer", Cancer Discov, 4, pp.1046~1061 (2014)
28. Ross HJ, "Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer", Clin Cancer Res, 16, pp.1938~1949 (2010)
29. Zhang D, "Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells", Mol Cancer Ther, 7, pp.1846~1850 (2008)
30. Anido J, "ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR", HER2 and EGFR, Clin Cancer Res, pp.2003, 9[DOI]
31. Rusnak DW, "The characterization of novel, dual ErbB-2", EGFR, tyrosine kinase inhibitors: potential therapy for cancer, 2001, pp.61, 7196~7203
32. Kurokawa H, "Inhibition of HER2", neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells, 2000, pp.60, 5887~5894
33. Rabindran SK, "Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase", Cancer Res, 64, pp.3958~3965 (2004)
34. Hirsh V, "Afatinib(BIBW 2992)development in non-small-cell lung cancer", Future Oncol, 7, pp.817~825 (2011)
35. Nunes M, "Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes", Mol Cancer Ther, 3, pp.21~27 (2004)
36. Engelman JA, "PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib", Cancer Res, 67, pp.11924~11932 (2007)
37. Harris RC, "EGF receptor ligands", Exp Cell Res, 284, pp.2~13 (2003)
38. Yarden Y, "Untangling the ErbB signalling network", Nat Rev Mol Cell Biol, 2, pp.127~137 (2001)
39. Burgess AW, "An open-and-shut case? Recent insights into the activation of EGF", ErbB receptors, 2003, pp.12, 541~552
40. Moulder SL, "Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2", neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo, 2001, pp.61, 8887~8895
41. Citri A, "The deaf and the dumb : the biology of ErbB-2 and ErbB-3", Exp Cell Res, 284, pp.54~65 (2003)
42. 남호우, "GRA Proteins of Toxoplasma gondii: Maintenance of Host-Parasite Interactions across the Parasitophorous Vacuolar Membrane", The Korean Journal of Parasitology, 47, pp.29~37 (2009), 대한기생충학ㆍ열대의학회
43. Eto K, "Loss of programmed cell death 4 induces apoptosis by promoting the translation of procaspase-3 mRNA", Cell Death Differ, 19, pp.573~581 (2012)
44. Rosowski EE, "Toxoplasma gondii inhibits gamma interferon(IFN-γ)-and IFN-β-induced host cell STAT1 transcriptional activity by increasing the association of STAT1 with DNA", Infect Immun, 82, pp.706~719 (2014)

관련 논문AI추천